Research Analysts Offer Predictions for LRMR Q2 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at William Blair lifted their Q2 2025 earnings estimates for Larimar Therapeutics in a report released on Wednesday, April 30th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($0.50) for the quarter, up from their previous forecast of ($0.51). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics' FY2025 earnings at ($1.99) EPS, Q1 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.51) EPS and FY2026 earnings at ($2.05) EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

LRMR has been the topic of several other research reports. Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Guggenheim restated a "buy" rating and issued a $26.00 target price on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Truist Financial initiated coverage on Larimar Therapeutics in a research report on Wednesday, January 29th. They set a "buy" rating and a $18.00 price target for the company. Robert W. Baird cut their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, March 25th. Finally, HC Wainwright lifted their target price on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, March 25th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $19.63.

Larimar Therapeutics Stock Performance

Shares of LRMR stock remained flat at $2.24 during trading hours on Monday. The stock had a trading volume of 168,842 shares, compared to its average volume of 751,119. Larimar Therapeutics has a 1-year low of $1.61 and a 1-year high of $11.20. The stock has a market cap of $143.42 million, a PE ratio of -1.95 and a beta of 0.93. The firm has a 50-day moving average price of $2.31 and a two-hundred day moving average price of $4.10.

Institutional Investors Weigh In On Larimar Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in Larimar Therapeutics during the fourth quarter valued at $25,000. Virtu Financial LLC acquired a new stake in shares of Larimar Therapeutics during the 3rd quarter valued at about $71,000. Algert Global LLC purchased a new position in shares of Larimar Therapeutics in the 4th quarter valued at about $47,000. China Universal Asset Management Co. Ltd. acquired a new position in Larimar Therapeutics in the 4th quarter worth about $52,000. Finally, Graham Capital Management L.P. purchased a new position in Larimar Therapeutics during the fourth quarter worth approximately $54,000. Institutional investors and hedge funds own 91.92% of the company's stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.